105 related articles for article (PubMed ID: 14657596)
1. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Yasuda K; Igishi T; Kawasaki Y; Yamamoto M; Kato K; Matsumoto S; Kotani M; Sako T; Shigeoka Y; Sugitani A; Histuda Y; Shimizu E
Oncology; 2003; 65(3):224-8. PubMed ID: 14657596
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments.
Yasuda K; Igishi T; Kawasaki Y; Kato K; Matsumoto S; Katayama S; Sako T; Shigeoka Y; Suyama H; Sugitani A; Yamamoto M; Hitsuda Y; Shimizu E
Oncology; 2004; 66(5):347-52. PubMed ID: 15331920
[TBL] [Abstract][Full Text] [Related]
3. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
[TBL] [Abstract][Full Text] [Related]
7. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Kruijtzer CM; Schellens JH; Mezger J; Scheulen ME; Keilholz U; Beijnen JH; Rosing H; Mathôt RA; Marcus S; van Tinteren H; Baas P
J Clin Oncol; 2002 Dec; 20(23):4508-16. PubMed ID: 12454106
[TBL] [Abstract][Full Text] [Related]
8. Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.
Juan O; Albert A; Villarroya T; Sánchez R; Casan R; Caranana V; Campos JM; Alberola V
Neoplasma; 2003; 50(3):204-9. PubMed ID: 12937854
[TBL] [Abstract][Full Text] [Related]
9. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)].
Leutz M; Schlimmer P; Zell L; Ukena D; Sybrecht G
Pneumologie; 1997 Jan; 51(1):62-5. PubMed ID: 9132749
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of weekly paclitaxel in advanced lung cancer.
Akerley W; Glantz M; Choy H; Rege V; Sambandam S; Joseph P; Yee L; Rodrigues B; Wingate P; Leone L
J Clin Oncol; 1998 Jan; 16(1):153-8. PubMed ID: 9440737
[TBL] [Abstract][Full Text] [Related]
13. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
14. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
17. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Esteban E; González de Sande L; Fernández Y; Corral N; Fra J; Muñiz I; Vieitez JM; Palacio I; Fernández JL; Estrada E; Lacave AJ;
Ann Oncol; 2003 Nov; 14(11):1640-7. PubMed ID: 14581272
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
20. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
